Covid19
Conditions
Keywords
Sofosbuvir, Daclatasvir
Brief summary
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment
Interventions
DRUGSofosbuvir 400 MG/ Daclatasvir 60mg
Giving these two drugs for treatment of COVID patients
Sponsors
Alexandria University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* mild- moderate COVID-19 confirmed by PCR
Exclusion criteria
1. Patients on renal dialysis 2. Severe COVID-19 cases 3. Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia). 4. Children \< 12 years 5. Pregnant and breast feeding women 6. Exacerbation of hepatitis B
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19. | it is estimated to be 2 weeks | The study assesses the incidence of resolution of symptoms in COVID patients after taking Sofosbuvir and Daclatasvir for 14 days by doing PCR and the result to be negative |
Countries
Egypt
Outcome results
None listed